Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | CALCR | P30988 | 5/20 | 0.53 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.50 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15130591 | 1.00 | OPRM1 (0.55) | OPRM1OPRD1OPRK1KEAP1SLC6A2 | |
| SCHEMBL30163263 | 1.00 | OPRM1 (0.55) | OPRM1OPRD1OPRK1KEAP1SLC6A2 | |
| SCHEMBL14549930 | 1.00 | OPRM1 (0.55) | OPRM1OPRD1OPRK1KEAP1SLC6A2 | |
| SCHEMBL28846618 | 1.00 | OPRM1 (0.55) | OPRM1OPRD1OPRK1KEAP1SLC6A2 | |
| SCHEMBL30163405 | 0.99 | OPRM1 (0.56) | OPRM1OPRD1OPRK1KEAP1SLC6A2 | |
| SCHEMBL30163248 | 0.99 | OPRM1 (0.55) | OPRM1OPRD1OPRK1KEAP1SLC6A2 | |
| SCHEMBL29597272 | 0.98 | OPRM1 (0.55) | OPRM1OPRD1OPRK1KEAP1SLC6A2 | |
| SCHEMBL14549924 | 0.97 | KEAP1 (0.56) | OPRM1OPRD1OPRK1KEAP1SLC6A2 | |
| SCHEMBL11997748 | 0.97 | KEAP1 (0.56) | OPRM1OPRD1OPRK1KEAP1SLC6A2 | |
| SCHEMBL30163250 | 0.97 | KEAP1 (0.56) | OPRM1OPRD1OPRK1KEAP1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3846788-B1 | PDE11 INHIBITORS FOR USE FOR THE TREATMENT OF PARKINSON'S DISEASE | UNIV AMSTERDAM (NL) | 2025-10-29 | — | — | EP | disclosed |
| EP-4606386-A2 | SPECIFIC INCREASE OF DOPAMINE SYNTHESIS THROUGH TARGETING OF THE GUANYLATE CYCLASE 2C RECEPTOR IN THE TREATMENT OF PARKINSON S DISEASE | Universiteit van Amsterdam (NL) | 2025-08-27 | — | — | EP | disclosed |
| EP-3589305-B1 | SPECIFIC INCREASE OF DOPAMINE SYNTHESIS THROUGH TARGETING OF THE GUANYLATE CYCLASE 2C RECEPTOR IN THE TREATMENT OF PARKINSON'S DISEASE | UNIV AMSTERDAM (NL) | 2025-07-02 | — | — | EP | disclosed |
| CN-114195855-B | Solid phase synthesis method for polypeptide containing three pairs of disulfide bonds by introducing one pair of disulfide bonds | 深圳翰宇药业股份有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-118359685-A | Preparation method of linaclotide | 成都倍特药业股份有限公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-117530912-A | Stable solid formulations of guanylate cyclase-C receptor agonist polypeptides suitable for oral administration | 硬木药品公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-114195855-A | Solid-phase synthesis method for polypeptide containing three pairs of disulfide bonds by introducing one pair of disulfide bonds | 深圳翰宇药业股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-107936094-A | The synthetic method that a kind of solid liquid phase of Li Laluo peptides is combined | 江苏诺泰澳赛诺生物制药股份有限公司 | 2018-04-20 | — | — | CN | disclosed |